These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 9026938)

  • 1. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
    Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
    Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
    Iakovleva SV; Andreeva NE; Izgorodin AS
    Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
    Kraj M; Maj S; Pogłód R; Rostkowska J
    Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic significance of beta-2-microglobulin in multiple myeloma].
    Podol'tseva EI; Morozova EV; Almazov VA
    Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
    Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A study of the significance of serum beta 2-microglobulin levels in patients with multiple myeloma--analyzes as a marker of renal dysfunction and as a marker of tumor cell mass].
    Nishinarita S; Shimada H; Suzuki R; Kishigami Y; Sawada U; Horie T
    Rinsho Ketsueki; 1996 Mar; 37(3):201-7. PubMed ID: 8727343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
    Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
    Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
    Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
    Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of asymptomatic multiple myeloma.
    Alexanian R; Barlogie B; Dixon D
    Arch Intern Med; 1988 Sep; 148(9):1963-5. PubMed ID: 2458080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
    Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
    Scudla V; Vavrdová V; Budíková M; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
    Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
    Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.